April 25th 2024
A recent survey covered topics including skin-aging prevention, care-seeking behavior, trust in professionals, and more.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Botulinum Type A: Key Clinical Postulates
October 23rd 2021Botulinum type A injections are widely used across the dermatology and aesthetic medicine specialties. At the Fall Clinical Dermatology Conference 2021, Mark S Nestor, MD, PhD, highlights how to optimize the neurotoxin to improve patient care.
Meet the Aesthetic Expert with Dr Will Kirby: Joe Niamtu, III, DMD
October 5th 2021In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Joe Niamtu, III, DMD, a certified cosmetic facial, oral, and maxillofacial surgeon, about what it means to be a KOL, his journey in aesthetics, and why investing in practice staff is always a good idea.
Galderma, Sofregen Enter Agreement to Develop Silk-based Biostimulators
September 28th 2021Galderma and Sofregen Medical announced they have entered into an agreement to co-develop a novel line of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.